Form 4: Oruka CMO Exercises Options, Sells Shares

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, exercised stock options and warrants, then sold a portion of her common stock holdings under a pre-arranged trading plan.

Summary

• Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc. (ORKA), exercised 3,500 employee stock options at an exercise price of $6.84 per share on December 19, 2025.
• Goncalves also exercised 3,500 employee warrants at an exercise price of $7.80 per share on December 19, 2025.
• Concurrently, Goncalves sold a total of 7,000 shares of common stock in multiple transactions on December 19, 2025, at weighted average prices ranging from $28.5322 to $31.579 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan that was established on September 19, 2025.
• Following these transactions, Goncalves' direct beneficial ownership of Oruka Therapeutics common stock decreased from 5,018 shares to 1,518 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be seen negatively, these transactions are routine for executives realizing compensation gains, especially when conducted under a 10b5-1 plan. The significant profit margin on the sales is a positive for the insider, but the net reduction in beneficial ownership is a slight negative for external perception.

Positives

• The Chief Medical Officer exercised options and warrants, indicating a realization of value from her compensation package.
• The sales were executed at significantly higher prices (ranging from $28.53 to $31.58) than the exercise prices ($6.84 and $7.80), demonstrating a substantial gain for the insider.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests pre-planned, non-discretionary sales and reduces concerns about opportunistic insider selling.

Negatives

• The Chief Medical Officer reduced her direct beneficial ownership of the company's common stock by 3,500 shares (from 5,018 to 1,518 shares).
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Future Outlook

NA

Industry Context

This filing details an individual insider transaction, which is a routine event for executives managing their equity compensation. It does not provide direct insights into broader industry trends or competitive dynamics within the biotechnology sector, beyond the general context of executive compensation and equity management.

Related Party Transactions

• Joana Goncalves, Chief Medical Officer, engaged in transactions involving Oruka Therapeutics, Inc. common stock, including the exercise of employee stock options and warrants, and subsequent sales of shares. These are considered related party transactions as they involve an executive and the company's securities.

Stakeholder Impact

• Shareholders: May view the insider selling as a slight negative, though the 10b5-1 plan mitigates concerns. The transactions demonstrate an executive realizing value from their equity compensation.
• Employees: The exercise of options and warrants by a senior executive can be seen as a normal part of compensation realization.
• Company: The transactions are routine and do not directly impact company operations or financial health.

Key Dates

Recommendation

The filing details routine insider transactions (option/warrant exercise and subsequent sales) executed under a Rule 10b5-1 plan. While the Chief Medical Officer reduced her direct beneficial ownership, this is a common practice for executives to diversify holdings and realize compensation. The transactions do not provide new fundamental information about the company's operational performance or future prospects that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions while awaiting further company-specific news or financial updates.

Keywords

Oruka Therapeutics, ORKA, SEC Form 4, Insider Trading, Stock Option Exercise, Warrant Exercise, Share Sale, Rule 10b5-1, Chief Medical Officer, Joana Goncalves, Biotechnology, Pharmaceuticals